FDA approves Symvess, an acellular tissue-engineered vessel

The U.S. Food and Drug Administration has approved Symvess, the first acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to prevent imminent limb loss.

Leave A Comment

Your email address will not be published. Required fields are marked *